Regeneron Pharmaceuticals, Inc. (REGN) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
↑
18.07
+11% vs avg
5yr avg: 16.29
30Y Low7.7·High52.9
P/FCF
↑
18.35
-8% vs avg
5yr avg: 19.90
30Y Low10.9·High179.5
P/B Ratio
↓
2.50
↓-25% vs avg
5yr avg: 3.34
30Y Low1.7·High18.3
ROE
↓
14.9%
↑-39% vs avg
5yr avg: 24.4%
30Y Low-76%·High87%
Debt/EBITDA
↑
0.66
↑+27% vs avg
5yr avg: 0.52
30Y Low0.3·High9.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
REGN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Regeneron Pharmaceuticals, Inc. trades at 17.4x earnings, roughly in line with its 5-year average of 18.0x, sitting at the 20th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 22%. On a free-cash-flow basis, the stock trades at 18.4x P/FCF, 8% below the 5-year average of 19.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $74.9B | $83.8B | $82.0B | $99.9B | $81.9B | $70.9B | $55.6B | $43.0B | $42.9B | $43.6B | $42.7B |
| Enterprise Value | $74.5B | $83.4B | $82.2B | $99.8B | $81.5B | $70.7B | $56.1B | $42.1B | $42.1B | $43.5B | $42.6B |
| P/E Ratio → | 17.38 | 18.61 | 18.58 | 25.26 | 18.88 | 8.77 | 15.83 | 20.34 | 17.54 | 36.36 | 47.67 |
| P/S Ratio | 5.22 | 5.84 | 5.77 | 7.61 | 6.73 | 4.41 | 6.54 | 6.56 | 6.39 | 7.42 | 8.78 |
| P/B Ratio | 2.50 | 2.68 | 2.79 | 3.84 | 3.61 | 3.78 | 5.04 | 3.88 | 4.90 | 7.09 | 9.60 |
| P/FCF | 18.35 | 20.54 | 22.37 | 27.23 | 18.51 | 10.85 | 27.75 | 21.51 | 23.66 | 42.12 | 43.83 |
| P/OCF | 15.04 | 16.84 | 18.55 | 21.74 | 16.33 | 10.01 | 21.24 | 17.71 | 19.53 | 33.34 | 28.73 |
P/E links to full P/E history page with 30-year chart
REGN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Regeneron Pharmaceuticals, Inc.'s enterprise value stands at 18.1x EBITDA, 11% above its 5-year average of 16.3x. The Healthcare sector median is 14.1x, placing the stock at a 28% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.82 | 5.79 | 7.61 | 6.69 | 4.40 | 6.60 | 6.42 | 6.28 | 7.40 | 8.77 |
| EV / EBITDA | 18.07 | 20.24 | 18.38 | 20.93 | 14.23 | 7.65 | 14.72 | 17.41 | 15.70 | 19.54 | 29.70 |
| EV / EBIT | 20.82 | 15.81 | 17.00 | 23.37 | 16.57 | 7.53 | 14.51 | 17.13 | 16.31 | 20.66 | 31.89 |
| EV / FCF | — | 20.44 | 22.43 | 27.22 | 18.42 | 10.82 | 28.00 | 21.06 | 23.24 | 42.02 | 43.78 |
REGN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Regeneron Pharmaceuticals, Inc. earns an operating margin of 24.9%. Operating margins have compressed from 33.2% to 24.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 14.9% is modest. ROIC of 8.9% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.4% | 85.4% | 86.1% | 82.9% | 86.0% | 83.1% | 84.0% | 85.1% | 91.3% | 90.8% | 91.7% |
| Operating Margin | 24.9% | 24.9% | 28.1% | 33.2% | 44.2% | 55.7% | 42.1% | 33.7% | 37.8% | 35.4% | 27.4% |
| Net Profit Margin | 31.4% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 36.4% | 20.4% | 18.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 14.9% | 14.9% | 16.0% | 16.3% | 20.9% | 54.2% | 31.8% | 21.3% | 32.8% | 22.6% | 22.1% |
| ROA | 11.5% | 11.5% | 12.5% | 12.7% | 15.9% | 37.9% | 22.0% | 15.9% | 23.8% | 15.2% | 14.2% |
| ROIC | 8.9% | 8.9% | 10.8% | 13.5% | 19.8% | 44.6% | 24.7% | 18.2% | 27.1% | 29.9% | 26.2% |
| ROCE | 10.2% | 10.2% | 12.6% | 15.6% | 22.6% | 49.7% | 26.3% | 19.2% | 28.3% | 31.1% | 25.3% |
REGN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Regeneron Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 0.7x, which is very conservative (80% below the sector average of 3.3x). The company holds a net cash position — cash of $3.1B exceeds total debt of $2.7B, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 120.4x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.09 | 0.10 | 0.12 | 0.14 | 0.24 | 0.06 | 0.08 | 0.11 | 0.11 |
| Debt / EBITDA | 0.66 | 0.66 | 0.60 | 0.57 | 0.47 | 0.29 | 0.71 | 0.29 | 0.26 | 0.32 | 0.34 |
| Net Debt / Equity | — | -0.01 | 0.01 | -0.00 | -0.02 | -0.01 | 0.05 | -0.08 | -0.09 | -0.02 | -0.01 |
| Net Debt / EBITDA | -0.10 | -0.10 | 0.05 | -0.01 | -0.07 | -0.02 | 0.13 | -0.37 | -0.28 | -0.05 | -0.04 |
| Debt / FCF | — | -0.10 | 0.06 | -0.01 | -0.09 | -0.03 | 0.25 | -0.45 | -0.42 | -0.11 | -0.06 |
| Interest Coverage | 120.42 | 120.42 | 87.59 | 58.52 | 82.80 | 163.75 | 67.97 | 81.43 | 91.55 | 83.75 | 185.82 |
Net cash position: cash ($3.1B) exceeds total debt ($2.7B)
REGN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Regeneron Pharmaceuticals, Inc.'s current ratio of 4.13x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.39x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.69x to 4.13x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.13 | 4.13 | 4.73 | 5.69 | 5.06 | 3.56 | 3.63 | 3.67 | 5.52 | 4.93 | 3.15 |
| Quick Ratio | 3.39 | 3.39 | 3.95 | 4.94 | 4.29 | 3.07 | 2.91 | 2.99 | 4.72 | 4.29 | 2.83 |
| Cash Ratio | 1.97 | 1.97 | 2.28 | 3.17 | 2.46 | 1.45 | 1.33 | 1.53 | 1.95 | 1.24 | 0.84 |
| Asset Turnover | — | 0.35 | 0.38 | 0.40 | 0.42 | 0.63 | 0.50 | 0.44 | 0.57 | 0.67 | 0.70 |
| Inventory Turnover | 0.66 | 0.66 | 0.64 | 0.87 | 0.71 | 1.40 | 0.71 | 0.69 | 0.51 | 0.75 | 1.01 |
| Days Sales Outstanding | — | 146.10 | 159.65 | 157.70 | 159.78 | 137.09 | 176.75 | 155.05 | 122.01 | 122.72 | 121.03 |
REGN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Regeneron Pharmaceuticals, Inc. returns 5.8% to shareholders annually — split between a 0.5% dividend yield and 5.3% buyback yield. The payout ratio of 8.2% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 5.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.5% | 0.4% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | 8.2% | 8.2% | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.8% | 5.4% | 5.4% | 4.0% | 5.3% | 11.4% | 6.3% | 4.9% | 5.7% | 2.8% | 2.1% |
| FCF Yield | 5.4% | 4.9% | 4.5% | 3.7% | 5.4% | 9.2% | 3.6% | 4.6% | 4.2% | 2.4% | 2.3% |
| Buyback Yield | 5.3% | 4.7% | 4.4% | 2.9% | 3.1% | 3.8% | 11.7% | 1.1% | 0.4% | 0.7% | 0.3% |
| Total Shareholder Yield | 5.8% | 5.2% | 4.4% | 2.9% | 3.1% | 3.8% | 11.7% | 1.1% | 0.4% | 0.7% | 0.3% |
| Shares Outstanding | — | $109M | $115M | $114M | $114M | $112M | $115M | $115M | $115M | $116M | $116M |
Peer Comparison
Compare REGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 REGNYou | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 BIIB | $28B | 21.6 | 11.4 | 13.7 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 VRTX | $109B | 27.9 | 21.7 | 34.1 | 85.0% | 39.4% | 22.5% | 23.0% | 0.8 |
 INCY | $20B | 15.6 | 11.8 | 14.7 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 BMRN | $11B | 30.3 | 16.0 | 14.5 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 LLY | $933B | 43.0 | 31.0 | 104.0 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 AMGN | $179B | 23.3 | 14.1 | 22.1 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 GILD | $170B | 358.7 | 42.1 | 16.5 | 78.3% | 5.8% | 2.3% | 3.2% | 6.0 |
 MRK | $280B | 15.6 | 10.8 | 22.7 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full REGN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See REGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs REGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare REGN vs BIIB
Side-by-side business, growth, and profitability comparison vs Biogen Inc..
Start ComparisonREGN — Frequently Asked Questions
Quick answers to the most common questions about buying REGN stock.
What is Regeneron Pharmaceuticals, Inc.'s P/E ratio?
Regeneron Pharmaceuticals, Inc.'s current P/E ratio is 17.4x. The historical average is 38.4x. This places it at the 20th percentile of its historical range.
What is Regeneron Pharmaceuticals, Inc.'s EV/EBITDA?
Regeneron Pharmaceuticals, Inc.'s current EV/EBITDA is 18.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.8x.
What is Regeneron Pharmaceuticals, Inc.'s ROE?
Regeneron Pharmaceuticals, Inc.'s return on equity (ROE) is 14.9%. The historical average is -3.0%.
Is REGN stock overvalued?
Based on historical data, Regeneron Pharmaceuticals, Inc. is trading at a P/E of 17.4x. This is at the 20th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Regeneron Pharmaceuticals, Inc.'s dividend yield?
Regeneron Pharmaceuticals, Inc.'s current dividend yield is 0.47% with a payout ratio of 8.2%.
What are Regeneron Pharmaceuticals, Inc.'s profit margins?
Regeneron Pharmaceuticals, Inc. has 85.4% gross margin and 24.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Regeneron Pharmaceuticals, Inc. have?
Regeneron Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.